	US 12,269,855 B2
	Interleukin-2 and use thereof
Lishan Kang, Jiangsu (CN); Chunyin Gu, Jiangsu (CN); Fenggen Fu, Jiangsu (CN); Shuaixiang Zhou, Jiangsu (CN); Xinzhen Shi, Jiangsu (CN); and Junjian Liu, Jiangsu (CN)
Assigned to INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
Appl. No. 17/059,583
Filed by INNOVENT BIOLOGICS (SUZHOU) CO., LTD., Jiangsu (CN)
PCT Filed Sep. 20, 2019, PCT No. PCT/CN2019/107055 § 371(c)(1), (2) Date Nov. 30, 2020, PCT Pub. No. WO2020/057646, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 201811108649.X (CN), filed on Sep. 21, 2018.
Prior Publication US 2021/0221863 A1, Jul. 22, 2021
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01); A61K 47/68 (2017.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); C12P 21/02 (2006.01)

CPC C07K 14/55 (2013.01) [A61K 47/6843 (2017.08); A61K 47/6845 (2017.08); A61K 47/6853 (2017.08); A61K 47/6865 (2017.08); A61K 47/6871 (2017.08); C07K 16/18 (2013.01); C07K 16/248 (2013.01); C07K 16/3007 (2013.01); C07K 16/3053 (2013.01); C07K 16/40 (2013.01); C12P 21/02 (2013.01); A61K 38/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

12 Claims

1. An IL-2 mutant protein, comprising at least one mutation compared with a wild-type IL-2 comprising the amino acid sequence of SEQ ID NO:1, wherein the mutant protein has an eliminated or reduced binding affinity for an IL-2Rα receptor and/or an enhanced binding affinity for an IL-2Rß receptor, wherein the IL-2 mutant protein comprises mutations of K35/T37E/R38/F42 at positions corresponding to positions in SEQ ID NO: 1.